Welcome to Discussions

Posted on: Tue, Apr 8 2008 9:52 AM

Posted by: squiffy2 Posts: 68

GW Phamaceuticals said its pioneering cannabis-based medicine failed to show significant improvement in a final stage trial to treat neuropathic pain in multiple sclerosis (MS) patients.

GW said Sativex had a very high patient response rate in the trial but that the results narrowly failed to reach statistical significance due to an unexpectedly large placebo response.

"While valid, this indicates that the effect of Sativex is marginal, and we retain our doubts as to whether the product will ever prove a commercial success," KBC Peel Hunt analyst Paul Cuddon wrote in a research note.

Nomura analyst Gary Waanders described the result as disappointing.............

For the full report please go to MSRC: MS Research News : Drugs : Sativex

Posted on: Sun, Apr 13 2008 2:47 PM

Posted by: Kara Posts: 2,287

I'm glad to see we're even able to read about studies that are close but not statistically sig. There was (IMO) a negative trend in the research for quite some time that only the significant studies were discussed...that doesn't tell us much about what's been tried.

I'm interested in why such a large placebo response...any ideas Squiffy?

Disaboom moderator


My personal blog: If the World Had Wheels

Posted on: Wed, Apr 16 2008 12:26 PM

Posted by: squiffy2 Posts: 68

hi Kara

I think the large placebo response was due to the MSers believing they were getting the "real thing" and illustrates the power of mind over matter...................just my humble opinion. :O)

squiffs

Posted on: Thu, Apr 17 2008 6:19 PM

Posted by: runaround Posts: 3

I could not agree with you more.